Clinical Trials Logo

Leukemia, Prolymphocytic, T-Cell clinical trials

View clinical trials related to Leukemia, Prolymphocytic, T-Cell.

Filter by:

NCT ID: NCT03989466 Active, not recruiting - Clinical trials for T-Cell Prolymphocytic Leukemia

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Start date: January 15, 2020
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with alemtuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving itacitinib and alemtuzumab may work better in treating patients with T-cell prolymphocytic leukemia compared to standard of care treatment.

NCT ID: NCT03873493 Completed - Cancer Clinical Trials

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Start date: January 14, 2020
Phase: Phase 2
Study type: Interventional

The main objective of this study is to evaluate the efficacy of the combination of venetoclax plus ibrutinib for treating adults with T-cell prolymphocytic leukemia (T-PLL).

NCT ID: NCT02863692 Recruiting - CLL Clinical Trials

Registry of the German CLL Study Group

CLL-Registry
Start date: August 2013
Phase:
Study type: Observational [Patient Registry]

Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T/Natural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation

NCT ID: NCT02742727 Recruiting - Clinical trials for Acute Myeloid Leukemia

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.

NCT ID: NCT02689453 Completed - Clinical trials for T-Cell Prolymphocytic Leukemia

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Start date: January 19, 2017
Phase: Phase 1
Study type: Interventional

Background: Adult T-cell leukemia (ATL) is a rare blood cancer. Researchers want to see if a combination of two drugs - recombinant human interleukin 15 (rhIL-15) and alemtuzumab - is a better treatment for ATL. Objectives: To test if giving rhIL-15 combined with alemtuzumab improves the outcome of therapy for ATL. Also, to determine the safe dose of this combination and identify side effects and effects on the immune system. Eligibility: Adults 18 years and older with chronic or acute ATL who have not been helped by other treatments. Design: Participants will be screened with tests that are mostly part of their usual cancer care. They will sign a separate consent form for this. Weeks 1 and 2: Participants will have a total of 10 visits. They will: - Get rhIL-15 under the skin by needle. - Have a physical exam and vital signs measured. - Give blood samples. - Answer questions about their health and their medicines. Week 3: Participants will stay in the clinic. They will: - Get alemtuzumab infusions in a vein through a small catheter on days 1, 2, 3, and 5. - Take medicines to decrease side effects. - Have a computed tomography (CT) scan to evaluate the treatment. - Have a physical exam and vital signs measured. - Give blood samples. Answer questions about their health and medicines. Weeks 4, 5, and 6 will repeat week 3, without the CT scan. Some patients will just have outpatient visits these weeks. After treatment, participants will have follow-up visits every few months for up to 2 years. At these visits, participants will give blood samples and have CT scans.

NCT ID: NCT02512497 Recruiting - Clinical trials for Peripheral T-Cell Lymphoma

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Start date: December 8, 2017
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to learn if giving romidepsin before and after a stem cell transplant in combination with fludarabine and busulfan can help to control leukemia or lymphoma. Researchers also want to learn the highest tolerable dose of romidepsin that can be given with this combination. The safety of this combination and the safety of giving romidepsin after a stem cell transplant will also be studied. This is an investigational study. Romidepsin is FDA approved and commercially available for the treatment of CTCL in patients who have received at least 1 systemic (affecting the whole body) therapy before. Busulfan and fludarabine are FDA approved and commercially available for use with a stem cell transplant. The use of the combination of romidepsin, busulfan, and fludarabine to treat the type of leukemia or lymphoma you have is considered investigational. Up to 30 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT01251575 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Start date: December 1, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation together with sirolimus, cyclosporine, and mycophenolate mofetil before and after transplant may stop this from happening.

NCT ID: NCT01186640 Completed - Clinical trials for T-cell-prolymphocytic Leukemia

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

Start date: June 2010
Phase: Phase 2
Study type: Interventional

Study hypothesis: Simultaneous FMC-Alemtuzumab administration followed by Alemtuzumab maintenance therapy in patients with T-PLL is feasible, safe and efficient.

NCT ID: NCT01162031 Withdrawn - Leukemia Clinical Trials

Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

Start date: June 2010
Phase: Phase 2
Study type: Interventional

We hope to learn more about the clinical efficacy of bortezomib in T-cell prolymphocytic leukemia. Patients will be selected as a possible participant in this study because they have a bone marrow disorder known as T-cell prolymphocytic leukemia (T-cell PLL) which does not tend to respond well to conventional treatment with chemotherapy.

NCT ID: NCT01008462 Completed - Clinical trials for Recurrent Small Lymphocytic Lymphoma

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Start date: March 18, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia. Autologous stem cell transplantation uses the patient's stem cells and does not cause graft versus host disease (GVHD) and has a very low risk of death, while minimizing the number of cancer cells. Peripheral blood stem cell (PBSC) transplant uses stem cells from the patient or a donor and may be able to replace immune cells that were destroyed by chemotherapy. These donated stem cells may help destroy cancer cells. Bone marrow transplant known as a nonmyeloablative transplant uses stem cells from a haploidentical family donor. Autologous peripheral blood stem cell transplant followed by donor bone marrow transplant may work better in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia.